Abstract:Abstract Background Heart failure (HF) is a complex multifactorial syndrome characterized by mechanical dysfunction of the myocardium and the inability of the heart to provide adequate blood supply to meet the body's metabolic needs. Defects in mechanisms such as bioenergetics are important pathogenic factors in myocardial dysfunction, since the heart needs a continuous energy supply, which is fulfilled by ATP synthesis through mitochondrial oxidative phosphorylation, a process that takes place in the inner membrane of the mitochondria, whose structure is also affected during the development of HF. Purpose The aim of this study was to analyze the alterations in the expression level of mRNAs and proteins involved in mitochondrial function, focusing on bioenergetics and formation of cristae formation in patients with ischemic and dilated cardiomyopathy. Methods Transcriptome-level differences between HF and controls (CNT) were investigated in 36 heart samples with RNA-sequencing technology (mRNA-seq; ICM, n=13; DCM, n=13; CNT, n=10). In addition, ATP5I and ATPIF1 protein levels were determined in 30 heart samples (ICM, n=24; CNT, n=6) by Western Blot assay. The miRNAs implicated in the mRNA posttranscriptional regulation were studied through non-coding RNA-seq (ICM, n=22; DCM, n=20; CNT, n=8). Results 11 mitochondria genes were detected as altered in bioenergetics and mitochondrial cristae formation in HF. Specifically, we found an overexpression of ATP5I (ICM, FC=2.04, p<0.001) and ATPIF1 (ICM, FC=1.81, p<0.01) mRNA levels that correlated with both diastolic (r=-0.577 and r=-0.562, respectively; p<0.01) and systolic diameter (r=-0.574 and r=-0.563, respectively; p<0.01) and with ejection fraction (r=0.442 and r=0.410, respectively; p<0.05). The analysis of ATP5I and ATPIF1 protein expression showed that only ATPIF1 presented differences in expression when comparing patients with ischemic HF with the control group (FC=, 1.75, p<0.01). Furthermore, we observed alterations in ATP5I target miRNA, miR-483-3p (FC=1.37, p<0.01), which can induce dysregulation in its protein level. Conclusions The alterations of mitochondrial bioenergetics and cristae formation related molecules could reflect damage of the cardiac mitochondria function in HF, interfering in the critical activities of the cardiomyocyte and showing a significant relationship with the ventricular function.

Reduced mitochondrial pyruvate carrier expression in hearts with heart failure and reduced ejection fraction patients: ischemic vs. non-ischemic origin

Mitochondrial pyruvate carrier abundance mediates pathological cardiac hypertrophy

Mitochondrial pyruvate carriers are required for myocardial stress adaptation

Alterations of mitochondrial bioenergetics in human hearts with ischemic and dilated cardiomyopathy

Decreased Mitochondrial Pyruvate Transport Activity in the Diabetic Heart: ROLE OF MITOCHONDRIAL PYRUVATE CARRIER 2 (MPC2) ACETYLATION

Mitochondrial Pyruvate Carrier 1: a Novel Prognostic Biomarker That Predicts Favourable Patient Survival in Cancer

Mitochondrial ATPase and High-Energy Phosphates in Failing Hearts.

Loss of mitochondrial pyruvate transport initiates cardiac glycogen accumulation and heart failure

Alterations in Mitochondrial Oxidative Phosphorylation System: Relationship of Complex V and Cardiac Dysfunction in Human Heart Failure

Effects of Augmented Delivery of Pyruvate on Myocardial High-Energy Phosphate Metabolism at High Workstate

Mitochondrial Pyruvate Carrier 1 Alleviates Hypoxic-Ischemic Brain Injury in Rats.

The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure

The Role of Mitochondrial Pyruvate Carrier in Neurological Disorders

Enhancing mitochondrial pyruvate metabolism ameliorates ischemic reperfusion injury in the heart

The mitochondrial pyruvate carrier regulates adipose glucose partitioning in female mice

Mitochondrial Morphology, Dynamics, and Function in Human Pressure Overload or Ischemic Heart Disease With Preserved or Reduced Ejection Fraction

Fifty years of the mitochondrial pyruvate carrier: New insights into its structure, function, and inhibition

Hypoxia Induces Lactate Secretion and Glycolytic Efflux by Downregulating Mitochondrial Pyruvate Carrier Levels in Human Umbilical Vein Endothelial Cells.

Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction

CypD(-/-) hearts have altered levels of proteins involved in Krebs cycle, branch chain amino acid degradation and pyruvate metabolism.

Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease